Inhibition by antibiotics of the bacterial response to long-term starvation of Salmonella typhimurium and the colon microbiota of mice.
The number of viable cells of two strains of Salmonella typhimurium and the number of viable cells and the cell size of the colon microbiota of mice were examined during non-growing conditions after exposure to antibiotics with known modes of action. Salmonella typhimurium starved for 1, 2, 4, 5, 12 and 20 d in a phosphate buffer saline solution and subsequently exposed for 2 and 6 h showed the following characteristics. The protein synthesis inhibitors gentamicin and tetracycline, the RNA synthesis inhibitor rifampicin and the membrane potential inhibitor polymyxin all impaired survival of starved cells. The reduction in the number of viable cells caused by the addition of gentamicin, rifampicin and polymyxin was generally more pronounced with extended exposure to energy and nutrient deprivation. Both 2- and 6-h exposure of tetracycline, however, had diminishing inhibitory effects after 20 d compared with 5 d of starvation. Control experiments to verify non-growing conditions in the starvation regime showed that DNA and cell wall synthesis inhibitors had no inhibitory effect after 24-h starvation. The rough mutant strain displayed a lower sensitivity to a hydrophobic rather than a hydrophilic inhibitor as compared to the smooth wild-type strain. The cell size reduction but not viability was partly prevented by protein synthesis inhibitors as seen for both in vivo and in vitro colon microbiota studies.
Stenström
T A
TA
National Bacteriological Laboratory, Stockholm, Sweden.
Conway
P
P
Kjelleberg
S
S
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001426:Bacterial Proteins / Q000096:biosynthesis; D002473:Cell Wall / Q000187:drug effects; D003106:Colon / Q000382:microbiology*; D015169:Colony Count, Microbial; D005508:Food Deprivation; D005839:Gentamicins / Q000494:pharmacology / Q000627:therapeutic use; D007769:Lactams; D051379:Mice; D008807:Mice, Inbred BALB C; D009268:Nalidixic Acid / Q000494:pharmacology / Q000627:therapeutic use; D011113:Polymyxins / Q000494:pharmacology / Q000627:therapeutic use; D012329:RNA, Bacterial / Q000096:biosynthesis; D012293:Rifampin / Q000494:pharmacology / Q000627:therapeutic use; D012481:Salmonella Infections, Animal / Q000188:drug therapy / Q000382:microbiology*; D012486:Salmonella typhimurium / Q000187:drug effects* / Q000254:growth & development; D013752:Tetracycline / Q000494:pharmacology / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D005839:Gentamicins; D007769:Lactams; D011113:Polymyxins; D012329:RNA, Bacterial; D009268:Nalidixic Acid; D013752:Tetracycline; D012293:Rifampin